PMP22 and Charcot-Marie-Tooth disease type 1A: Given the slow progression of CMT1A, biomarkers that have capacity to demonstrate slowing of disease progression or improvement, prior to changes in physical functioning, neurologic impairment or symptoms, will enable go/no go decisions in early phase clinical trials in CMT1A.